Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1847 results
February 2018
-
Press release
Sandoz announces US FDA approval and launch of Glatopa® 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
Glatopa® 40 mg/mL is a fully substitutable, AP-rated generic version of Copaxone®* (glatiramer acetate injection) 40 mg/mL Glatopa 40 mg/mL, along with Glatopa® 20 mg/mL, which was launched… -
Story Discovery
Potential weight loss treatment takes shape with help from patients
Novartis researchers are partnering with advocacy groups to understand the stigma and challenges facing patients with obesity.
-
Press release
Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis
US label updated to include Cosentyx® (secukinumab) data in moderate-to-severe scalp psoriasis[1] - one of the difficult-to-treat types of psoriasis[2] Approximately half of all 125 million… -
Story Discovery
Compound designed to fight Alzheimer’s disease shows promise in the lab
The molecule restores the activity of neurons and neural circuits in a model of the disease.
-
Story Access to Healthcare
Partnering for improved cancer care around the globe
Novartis works tirelessly with third-party organizations to improve access to cancer care.
-
Story Access to Healthcare
Living with breast cancer in Uganda
Suzan Akello describes what life has been like since her cancer diagnosis.
-
Ad hoc release
Novartis completes subsequent offering period of the tender offer for Advanced Accelerator Applications S.A.
Basel, February 1, 2018 - Novartis AG (NYSE: NVS) today announced the completion of the subsequent offering period of the tender offer by its subsidiary, Novartis Groupe France S.A., to purchase all…
January 2018
-
Press release
Novartis announces NEJM publication of updated analysis from ELIANA trial showing longer-term durable remissions with Kymriah(TM) in children, young adults with r/r ALL
Analysis of 75 patients with median follow-up of more than a year demonstrated an overall remission rate of 81% Event-free survival and overall survival at six months were 73% and 90%, with… -
Press release
AveXis to Initiate Screening for Remaining Patients in Pivotal Trial of AVXS-101 for SMA Type 1 Following Review of Preliminary Data from First Three Patients
CHICAGO, Jan. 30, 2018 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening… -
Story Discovery
Tracking patients’ progress with radio signals and machine learning
Novartis researchers leverage in-house startup initiative to begin digital technology research collaboration.
-
Featured News
Novartis recognized as a global leader in sustainable water and climate management
Novartis is one of 73 companies included in the 2017 Water A List by CDP, the nonprofit global environmental disclosure platform.
-
Ad hoc release
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Lutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT) Advanced Accelerator Applications is a newly established subsidiary of Novartis Lutathera…